Thrombin Plasma Prep

De-fibrinate plasma before exosome isolation for efficient recovery and high yields.

  • Chugh PE, et al. Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies. PLoS Pathog. 2013. 9(7): e1003484. PMCID: PMC3715412.

Products

Catalog Number Description Size Price Quantity Add to Cart
TMEXO-1 Thrombin Plasma prep for Exosome precipitation (500 µL at 500 U/mL) 100 Reactions $541
- +

Overview

Overview

Efficient exosome isolation from plasma

"We therefore pursued the ExoQuick® method for further study, as these samples required much less sample input, a key benefit when working with clinical samples and mouse models1."

When isolating exosomes from plasma, fibrinogen and fibrin can impede efficient recovery. By pre-treating plasma with thrombin, the fibrinogen can be converted to fibrin and easily pre-cleared by a simple centrifugation step. The resulting serum-like solution can now be treated with ExoQuick, original formulation, for quantitative exosome isolation that is compatible with high-throughput methods.

Want to learn more about how ExoQuick works? Find out here.

Choose the right ExoQuick for your application:

ApplicationProductCatalog #
Purest EV isolationExoQuick ULTRA and
ExoQuick-TC ULTRA
EQULTRA-20A-1
EQULTRA-20TC-1
General purpose EV isolationExoQuick and
ExoQuick-TC
EXOQ20A-1
EXOTC50A-1
EV isolation for pre-clinical/in vivo studiesExoQuick-CGEXOCG50A-1
EV isolation that removes contaminating lipoprotein particles from plasma or serumExoQuick-LPEXOLP5A-1
EV isolation that includes a de-fibrinating plasma step prior to isolationExoQuick Plasma Prep with ThrombinEXOQ5TM-1

REFERENCES

  1. Chugh PE, et al. Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies. PLoS Pathog. 2013. 9(7): e1003484. PMCID: PMC3715412.

How It Works

Supporting Data

FAQs

Resources

Citations

Products

Catalog Number Description Size Price Quantity Add to Cart
TMEXO-1 Thrombin Plasma prep for Exosome precipitation (500 µL at 500 U/mL) 100 Reactions $541
- +

Overview

Overview

Efficient exosome isolation from plasma

"We therefore pursued the ExoQuick® method for further study, as these samples required much less sample input, a key benefit when working with clinical samples and mouse models1."

When isolating exosomes from plasma, fibrinogen and fibrin can impede efficient recovery. By pre-treating plasma with thrombin, the fibrinogen can be converted to fibrin and easily pre-cleared by a simple centrifugation step. The resulting serum-like solution can now be treated with ExoQuick, original formulation, for quantitative exosome isolation that is compatible with high-throughput methods.

Want to learn more about how ExoQuick works? Find out here.

Choose the right ExoQuick for your application:

ApplicationProductCatalog #
Purest EV isolationExoQuick ULTRA and
ExoQuick-TC ULTRA
EQULTRA-20A-1
EQULTRA-20TC-1
General purpose EV isolationExoQuick and
ExoQuick-TC
EXOQ20A-1
EXOTC50A-1
EV isolation for pre-clinical/in vivo studiesExoQuick-CGEXOCG50A-1
EV isolation that removes contaminating lipoprotein particles from plasma or serumExoQuick-LPEXOLP5A-1
EV isolation that includes a de-fibrinating plasma step prior to isolationExoQuick Plasma Prep with ThrombinEXOQ5TM-1

REFERENCES

  1. Chugh PE, et al. Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies. PLoS Pathog. 2013. 9(7): e1003484. PMCID: PMC3715412.

How It Works

Supporting Data

FAQs

Citations